Can Semaglutide (GLP-1) Affect Fertility?
Yes, but indirectly. Semaglutide (GLP-1) is not a fertility treatment, yet by improving insulin sensitivity, supporting weight loss and helping ovulation return, it can raise the chance of conception, particularly in women with obesity, insulin resistance or PCOS. This is the basis of the widely reported unexpected pregnancies on GLP-1 therapy. If you are not trying to conceive, that same restored fertility is exactly why reliable contraception matters. [1, 2]
Talk to a Karespot doctor →
Can Semaglutide (GLP-1) Affect Fertility?
It can, but indirectly. Semaglutide (GLP-1) is not a fertility medicine and contains no reproductive hormones. By improving insulin sensitivity and supporting weight loss, it can help ovulation return in women whose cycles were disrupted by obesity, insulin resistance or PCOS, which in turn can raise the chance of conception. The effect is a downstream benefit of better metabolic health, not a hormone acting directly on the ovaries.
Obesity and insulin resistance disrupt the hypothalamic-pituitary-ovarian axis, the hormonal signalling loop that drives ovulation, and can cause irregular or absent periods. Improving insulin sensitivity and losing weight helps rebalance these reproductive hormones, and for many women regular cycles return, a marker of restored ovulation and improved fertility potential. [2]
| A fertility treatment | Semaglutide (GLP-1) | |
|---|---|---|
| Designed to improve fertility? | Yes, that is its purpose | No, it is a weight and blood-sugar medicine |
| How it may affect ovulation | Acts directly to trigger or support ovulation | Indirectly, through weight loss and insulin sensitivity |
| Primary purpose | Help conception | Blood-sugar control and weight management |
| Use when trying to conceive | Used under specialist guidance | Usually stopped well before conception |
Semaglutide is not a fertility treatment and should not be used as one.
Why Does Losing Weight Bring Ovulation Back?
Body fat, insulin and energy balance all feed into the hormonal signals that control the ovaries. When excess weight and insulin resistance improve, that signalling can rebalance and ovulation can resume. Even modest weight loss is associated with more frequent ovulation and more regular cycles. This is the main, well-supported route by which GLP-1 therapy touches fertility.
The strongest evidence points to an indirect, metabolic pathway. At the same time, researchers have shown that GLP-1 receptors are present in reproductive tissues, including the ovary, so a small direct effect on ovarian function cannot yet be ruled out. Leading reviews describe this as an area that still needs more study rather than a settled question, which is why the honest answer is that fertility changes are mostly driven by weight and metabolism, with a possible direct role under investigation. [2, 5]
Indirect (via weight & metabolism)
Possible direct (on ovarian tissue)
What Are the "GLP-1 Babies"?
"GLP-1 babies" is the popular name for unexpected pregnancies reported among women using GLP-1 medicines, often after years of difficulty conceiving. The likely reason is that weight loss and improved insulin sensitivity restore ovulation in women whose cycles were previously irregular, especially with PCOS. Fertility returns quietly, while contraception has not been updated to match.
Unexpected pregnancies have been increasingly reported among women on GLP-1 receptor agonists, particularly those with previously irregular cycles or PCOS. This is not a mysterious drug effect. It is the predictable result of an anovulatory cycle becoming ovulatory again as metabolic health improves. If you are sexually active and not planning a pregnancy, this is the moment to discuss suitable contraception with your provider, before or during treatment. [1]
"Semaglutide restored my fertility" and "semaglutide is a fertility drug" are two different statements. The first describes a welcome side effect of better metabolic health. The second is a claim the medicine does not support. The practical takeaway is the same either way: if a regular cycle returns, so can the possibility of pregnancy.
Planning a Pregnancy: When Should You Stop Semaglutide (GLP-1)?
Stop the medicine at least two months before you plan to conceive, because semaglutide has a long washout period. It takes roughly five to seven weeks to clear the body, and a two-month buffer also gives time to stabilise your metabolic health. Never start or stop the medicine without medical advice, particularly if you have type 2 diabetes and need a plan to manage blood sugar.
A little planning ahead avoids exposure during early pregnancy, when fetal development is most sensitive. The timeline below shows why the two-month rule works and where the washout period fits within it. [3]
Semaglutide is not a fertility medicine. Any improvement in fertility is a side benefit of treating weight and metabolic health, not a designed effect. If conception is the goal, the medicine is usually stopped well before you try, and fertility itself is managed with the right specialist.
What If You Become Pregnant While Taking It?
Contact your healthcare provider promptly. Semaglutide is not recommended in pregnancy: animal reproduction studies have shown reproductive toxicity and human data are limited. Your provider will usually advise stopping the medicine and will discuss the safest plan, including how to manage blood sugar if you have type 2 diabetes.
An unexpected pregnancy on a GLP-1 can feel overwhelming, but the right next step is simple: speak to your doctor rather than stopping other essential treatment on your own. The three situations below cover where most people find themselves, and what each one calls for. [3, 4]
Whichever situation applies, the underlying theme is the same. As your metabolic health improves, your fertility can change, so your contraception and your pregnancy plan deserve to be revisited rather than assumed. A short conversation keeps the plan matched to your body. [1]
Thinking about fertility or pregnancy on a GLP-1?
Karespot coordinates preconception guidance on GLP-1 therapy, including safe timing to stop before conception, and brings in specialists for PCOS and insulin resistance alongside your reproductive goals.
Check your eligibility → Doctor-led care, available across IndiaFrequently Asked Questions
Can semaglutide (GLP-1) increase fertility?
How long before pregnancy should I stop semaglutide (GLP-1)?
What are "GLP-1 babies"?
Do I still need contraception on semaglutide (GLP-1)?
Is semaglutide safe during pregnancy?
Can I use semaglutide as a fertility treatment?
What should I do if I become pregnant while taking semaglutide?
Practice Committee of the American Society for Reproductive Medicine. Obesity and reproduction: a committee opinion. Fertil Steril. 2021;116(5):1266-1285.
asrm.org | Obesity and reproduction: a committee opinion (2021)Voros C, Chatzinikolaou F, Papapanagiotou I, et al. A systematic review on GLP-1 receptor agonists in reproductive health: integrating IVF data, ovarian physiology and molecular mechanisms. Int J Mol Sci. 2026;27(2):759.
doi.org/10.3390/ijms27020759Semaglutide Prescribing Information. U.S. Food & Drug Administration; 2023. (Discontinue at least 2 months before a planned pregnancy; based on animal reproduction studies there may be potential fetal risk.)
accessdata.fda.gov | Semaglutide Prescribing Information (2023)Sills ES, Harrity C, Chu HI, et al. Semaglutide and human reproduction: caution at the intersection of energy balance, ovarian function, and follicular development. Reprod Biol Endocrinol. 2025;23:116.
doi.org/10.1186/s12958-025-01435-7GLP-1 Receptor Agonists, Fertility Restoration, and Reproductive Safety in Women of Reproductive Age: a narrative review. J Clin Med. 2026;15(9):3204. (Confirms GLP-1 receptor expression in reproductive tissue; notes evidence remains insufficient to establish direct effects independent of weight loss.)
doi.org/10.3390/jcm15093204Dr. Prakrati Garg is a Research Associate and published researcher in Biotechnology at Shoolini University, and Content Strategist at Karespot. With expertise in herbal drug development, nanotechnology and drug delivery systems, she brings a rigorous scientific approach to Karespot's health and wellness content.
Dr. Sana Umar is an Assistant Professor at Doon Medical College and Medical Reviewer at Karespot. A Clinical Pathologist with FRCP credentials and NMC registration (Reg. 8506), she ensures all clinical content aligns with current prescribing guidelines and evidence-based best practices in GLP-1 therapy and women's metabolic health.
Obesity and metabolic health are complex, and navigating them alone is harder still.
That is why Karespot brings you expert, doctor-led care that is never limited to a single speciality. Depending on what your body needs, you are supported by the right specialists and super-specialists, working together across India.
Medical Disclaimer: This article is for general information and education. It is not a substitute for personalised medical advice. Semaglutide (GLP-1) is a prescription medicine; do not start, stop or change your dose without consulting a qualified healthcare professional. If you are pregnant, planning a pregnancy, or concerned about your fertility, speak to your doctor.
